Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 1, pp 19–23 | Cite as

Effect of bismuth nitrate given in combination withcis-diamminedichloroplatinum(II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor

  • Yukihiro Kondo
  • Masahiko Satoh
  • Nobumasa Imura
  • Masao Akimoto
Original Articles Cisplatin, Bismuth, Renal Toxicity, Human Bladder Tumor


The effects of bismuth nitrate pretreatment on the toxicity and antitumor activity ofcis-diamminedichloroplatinum (cisplatin, CDDP) were examined in nude mice that had been inoculated with human bladder-tumor tissue. Pretreatment with bismuth nitrate depressed the renal toxicity of CDDP without compromising its activity against a transplantable human bladder tumor. Renal metallothionein (MT) and bismuth (Bi) levels in nude mice were markedly increased by Bi preadministration, but no significant MT induction was observed in inoculated human bladder-tumor tissue in which only a trace amount of Bi was incorporated. Furthermore, it was confirmed that tumor platinum (Pt) concentrations in CDDP-treated mice were not affected by Bi pretreatment. Thus, the administration of Bi compounds prior to chemotherapy with CDDP may provide an effective mode of treatment for advanced bladder tumors.


Nitrate Platinum Cancer Research Bismuth Nude Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baldew GS, Hamer CJ van den, Los G, Vermeulen NP, Goeij JJ de, McVie JG (1889) Selenium-induced protection againstcis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats. Cancer Res 49: 3020Google Scholar
  2. 2.
    Borch RF, Katz JC, Lieder PH, Pleasants ME (1980) Effect of diethyldithiocarbamate resin on tumor response tocis-platinum in a rat model. Proc Natl Acad Sci USA 77: 5441Google Scholar
  3. 3.
    Brodie KG (1979) Analysis of arsenic and other trace elements by vapor generation. Am Lab 11: 58Google Scholar
  4. 4.
    Bühler RH, Kägi HR (1974) Human hepatic metallothioneins. FEBS Lett 39: 229Google Scholar
  5. 5.
    Corden BJ, Fine RL, Ozols RF, Collins M (1985) Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol 14: 38Google Scholar
  6. 6.
    Earhart RH, Martin PA, Tutsch KD, Erturk E, Wheeler RH, Bull FE (1983) Improvement of the therapeutic index of cisplatin by pharmacologically induced chloruresis in the rat. Cancer Res 43: 1187Google Scholar
  7. 7.
    Endresen L, Bakka A, Rugstad HE (1983) Increased resistance to chlorambucil in cytoplasmic metallothionein. Cancer Res 43: 2918Google Scholar
  8. 8.
    Hiratsuka A, Kawashima K, Watabe T (1986) Detoxication of ultimate carcinogens by rat liver zinc-metallothionein (in Japanese). J Hyg Chem 32: 10Google Scholar
  9. 9.
    Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitonealcis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43: 1426Google Scholar
  10. 10.
    Kotsonis FN, Klaassen CD (1978) Comparison of methods for estimating hepatic metallothionein in rats. Toxicol Appl Pharmacol 42: 583Google Scholar
  11. 11.
    Koyama Y, Nakatogawa K, Naganuma A, Imura N, Onosaka S, Tamaka K (1984) Effect of metallothionein inducing metals on toxicity of inorganic mercury. Jpn J Hyg 39: 385Google Scholar
  12. 12.
    Leber PA, Miya TS (1976) A mechanism for cadmium- and zinc-induced tolerance to cadmium toxicity: involvement of metallothionein. Toxicol Appl Pharmacol 37: 403Google Scholar
  13. 13.
    Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65: 307Google Scholar
  14. 14.
    Naganuma A, Satoh M, Yokoyama M, Imura N (1983) Selenium efficiently depressed toxic side effects ofcis-diamminedichloroplatinum. Res Commun Chem Pathol Pharmacol 42: 127Google Scholar
  15. 15.
    Naganuma A, Satoh M, Imura N (1984) Effect of selenite on renal toxicity and antitumor activity ofcis-diamminedichloroplatinum in mice inoculated with Ehrlich ascites tumor cells. J Pharmacobiocyn 7: 217Google Scholar
  16. 16.
    Naganuma A, Satoh M, Imura N (1987) Prevention of lethal and renal toxicity ofcis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res 47: 983Google Scholar
  17. 17.
    Naganuma A, Satoh M, Imura N (1988) Specific reduction of toxic side-effects of Adriamycin by induction of metallothionein in mice. Jpn J Cancer Res 79: 406Google Scholar
  18. 18.
    Nakajima N (1979) Studies on heterotransplantation of human urogenital malignant neoplasms (in Japanese). Jpn J Urol 70: 849Google Scholar
  19. 19.
    Ovejera AA, Houchens DP, Barker AD (1978) Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci 8: 50Google Scholar
  20. 20.
    Piotrowski JK, Bolanowska W, Sapata A (1973) Evaluation of metallothionein content in animal tissues. Acta Biochem Pol 20: 207Google Scholar
  21. 21.
    Satoh M, Naganuma A, Imura N (1988) Metallothionein induction prevents toxic side effects of cisplatin and Adriamycin used in combination. Cancer Chemother Pharmacol 21: 176Google Scholar
  22. 22.
    Satoh M, Naganuma A, Imura N (1988) Involvement of cardiac metallothionein in prevention of Adriamycin-induced lipid peroxidation in heart. Toxicology 53: 231Google Scholar
  23. 23.
    Satoh M, Miura N, Naganuma A, Matsuzaki N, Kawamura E, Imura N (1989) Prevention of adverse effects of γ-ray irradiation after metallothionein induction by bismuth subnitrate in mice. Eur J Cancer Clin Oncol 25: 1727Google Scholar
  24. 24.
    Satoh M, Naganuma A, Imura N (1989) Optimum schedule of selenium administration to reduce lethal and renal toxicities ofcis-diamminedichloroplatinum in mice. J Pharmcobiodyn 12: 246Google Scholar
  25. 25.
    Sharma RP, Edwards IR (1983)cis-Platinum: subcellular distribution and binding to cytosolic ligands. Biochem Pharmacol 32: 2665Google Scholar
  26. 26.
    Shiraishi N, Utsumi K, Morimoto S, Joja I, Iida S, Takeda Y, Aono K (1982) Inhibition of nitroblue tetrazolium reduction by metallothionein. Physiol Chem Phys 14: 533Google Scholar
  27. 27.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Witmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of urothelium. J Urol 133: 403Google Scholar
  28. 28.
    Sternberg JJ, Bracken RB, Handel PB, Johnson DE (1977) Combination chemotherapy (CISCA) for advanced urinary tract carcinoma: a preliminary report. JAMA 238: 2282Google Scholar
  29. 29.
    Szymanska JA, Mogilnicka EM, Kaszper BW (1977) Binding of bismuth in the kidneys of the rat: the role of metallothionein-like proteins. Biochem Pharmacol 26: 257Google Scholar
  30. 30.
    Thomas JP, Bachwoski GJ, Girotti AW (1986) Inhibition of cell membrane lipid peroxidation by cadmium- and zinc-metallothioneins. Biochim Biophys Acta 884: 448Google Scholar
  31. 31.
    Thornalley PJ, Vasak M (1985) Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydrogen radicals. Biochim Biophys Acta 827: 26Google Scholar
  32. 32.
    Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rosencweig M, Young RC, Muggia FM (1979) Toxic effects ofcis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63: 1527Google Scholar
  33. 33.
    Webb M (1976) Protection by zinc against cadmium toxicity. Biochem Pharmacol 21: 2767Google Scholar
  34. 34.
    Williams SD, Donohue JP, Einhorn LH (1979) Advanced bladder cancer: therapy withcis-dichlorodiammineplatinum(II), Adriamycin, and 5-fluorouracil. Cancer Treat Rep 63: 1573Google Scholar
  35. 35.
    Yagoda A (1983) Chemotherapy for advanced urothelial cancer. Semin Urol 1: 60Google Scholar
  36. 36.
    Yagoda A, Watson RD, Gonzalez-Vitale JC, Grabstald H, Whitmore WF (1976)cis-Dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat Rep 60: 917Google Scholar
  37. 37.
    Yoshikawa H (1976) Tolerance to acute metal toxicity in mice having received a daily injection of its low dose. Ind Health 12: 175Google Scholar
  38. 38.
    Zelazowski AJ, Garvey JS, Hoeschele JD (1984) In vivo and in vitro binding of platinum to metallothionein. Arch Biochem Biophys 229: 246Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Yukihiro Kondo
    • 1
  • Masahiko Satoh
    • 2
  • Nobumasa Imura
    • 2
  • Masao Akimoto
    • 1
  1. 1.Department of UrologyNippon Medical SchoolBunkyo-ku, TokyoJapan
  2. 2.Department of Public Health, School of Pharmaceutical SciencesKitasato UniversityMinato-ku, TokyoJapan

Personalised recommendations